However, biology is extremely complex and not deterministic. We also supply media and media additives for certain cell types. We are also developing workflows to enter new cell-based product markets. We commercialized Opto Viral Neutralization 1.0 in September 2020. Finally, we can export the cells for downstream analysis. Our platform is highly efficient for extracting information from small cell samples. Competition We face significant competition in the life sciences technology market. The currently issued in-licensed patents are expected to expire from 2022 to 2033. Our in-licensed patents and patent applications generally relate to micro opto-fluidics. Most Class I products are exempt from the premarket notification requirements. The contents of these websites are not incorporated into this filing. Our ability to execute on these alternative access channels is unproven. We may not be able to compete effectively against these organizations. As a result, our customers' needs are rapidly evolving. We may have difficulties locating, recruiting or retaining qualified sales people. Such a notice could harm our reputation and our ability to compete. Our actual or perceived failure to comply with such obligations could harm our business. In addition, certain key parts of our systems are manufactured by various third parties. Actual results may vary from our guidance and the variations may be material.